» Articles » PMID: 33893073

Interstitial Deletions Generating Fusion Genes

Overview
Date 2021 Apr 24
PMID 33893073
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

A fusion gene is the physical juxtaposition of two different genes resulting in a structure consisting of the head of one gene and the tail of the other. Gene fusion is often a primary neoplasia-inducing event in leukemias, lymphomas, solid malignancies as well as benign tumors. Knowledge about fusion genes is crucial not only for our understanding of tumorigenesis, but also for the diagnosis, prognostication, and treatment of cancer. Balanced chromosomal rearrangements, in particular translocations and inversions, are the most frequent genetic events leading to the generation of fusion genes. In the present review, we summarize the existing knowledge on chromosome deletions as a mechanism for fusion gene formation. Such deletions are mostly submicroscopic and, hence, not detected by cytogenetic analyses but by array comparative genome hybridization (aCGH) and/or high throughput sequencing (HTS). They are found across the genome in a variety of neoplasias. As tumors are increasingly analyzed using aCGH and HTS, it is likely that more interstitial deletions giving rise to fusion genes will be found, significantly impacting our understanding and treatment of cancer.

Citing Articles

Germline and Chimeras Generated by the Constitutional Translocation t(17;19)(q21;p13) in Two Siblings With Myelodysplastic Syndrome.

Panagopoulos I, Andersen K, Stavseth V, Torkildsen S, Heim S, Tandsaether M Cancer Genomics Proteomics. 2024; 21(3):272-284.

PMID: 38670586 PMC: 11059592. DOI: 10.21873/cgp.20446.


KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.

Fujii T, Nakano Y, Hagita D, Onishi N, Endo A, Nakagawa M Cancers (Basel). 2024; 16(1).

PMID: 38201436 PMC: 10778328. DOI: 10.3390/cancers16010009.


Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation.

Fadl A, Oishi N, Shi M, Dasari S, Ansell S, Ketterling R Hum Pathol. 2023; 141:6-14.

PMID: 37633531 PMC: 10840904. DOI: 10.1016/j.humpath.2023.08.007.


Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.

Kong Y, Jiang C, Wei G, Sun K, Wang R, Qiu T Molecules. 2023; 28(12).

PMID: 37375228 PMC: 10301843. DOI: 10.3390/molecules28124672.


Novel and Fusion Genes in T-cell Acute Lymphoblastic Leukemia.

Panagopoulos I, Andersen K, Johannsdottir I, Micci F, Heim S Cancer Genomics Proteomics. 2022; 20(1):51-63.

PMID: 36581344 PMC: 9806666. DOI: 10.21873/cgp.20364.


References
1.
Gai Z, Gui T, Muragaki Y . The function of TRPS1 in the development and differentiation of bone, kidney, and hair follicles. Histol Histopathol. 2011; 26(7):915-21. DOI: 10.14670/HH-26.915. View

2.
Capizzi E, DallOlio F, Gruppioni E, Sperandi F, Altimari A, Giunchi F . Clinical significance of ROS1 5' deletions in non-small cell lung cancer. Lung Cancer. 2019; 135:88-91. DOI: 10.1016/j.lungcan.2019.07.017. View

3.
Pavlick D, Schrock A, Malicki D, Stephens P, Kuo D, Ahn H . Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer. 2017; 64(8). DOI: 10.1002/pbc.26433. View

4.
Shah N, Lankerovich M, Lee H, Yoon J, Schroeder B, Foltz G . Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics. 2013; 14:818. PMC: 4046790. DOI: 10.1186/1471-2164-14-818. View

5.
Steidl C, Leimeister C, Klamt B, Maier M, Nanda I, Dixon M . Characterization of the human and mouse HEY1, HEY2, and HEYL genes: cloning, mapping, and mutation screening of a new bHLH gene family. Genomics. 2000; 66(2):195-203. DOI: 10.1006/geno.2000.6200. View